Latest Headlines
CATEGORY
-
2024-07-15Biosyngen’s BRG01 enters Phase II clinical trial, a first-in-kind autologous EBV-Specific CAR-T Therapy for Solid Tumors on Recurrent/Metastatic Nasopharyngeal CarcinomaBiosyngen, a leading biotechnology company focused on the development of innovative cell therapies, recently announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration(NMPA) in China has approved the initiation of a pivotal Phase ll clinical trial evaluatingREAD MORE -
2024-04-09Biosyngen reached a significant milestone in the Clinical Trial for BRG01, all patients for Phase 1 have completed dosing in less than a yearBiosyngen, an emerging biotech in the domain of immune cell therapy, pioneering multiple first-in-class products tailored for the treatment of various cancers such as nasopharyngeal cancer, liver cancer, digestive tract tumors, lung cancer, and other solid tumors. The company has secured eight cliniREAD MORE -
2024-02-01Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver CancerFebruary 1, 2024 - Biosyngen is proud to announce that its latest groundbreaking product, BST02, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of all types of liver cancer, including hepatocellular carcinoma and cholangiocarcinoma.READ MORE -
2024-01-24Biosyngen was granted an IND approval for its BST02, the world’s first TIL cell therapy for liver cancer to enter clinical trialOn January 23, 2024, Biosyngen announced that its independently developed TIL therapy BST02 has been granted an IND approval by the Center for Drug Evaluation (CDE), NMPA, China for the treatment of all types of liver cancer.READ MORE -
2024-01-16Biosyngen obtained IND approval from the NMPA China for its BRL03, a fourth-generation TCR therapy indicated for various solid tumors, including lung cancerEndorsed by Center for Drug Evaluation (CDE), NMPA, on January 15, 2024, Biosyngen’s third global exclusive product pipeline BRL03 was granted an IND approval for the treatment of advanced solid tumors, against lung cancer and gastric cancer.READ MORE -
2023-10-27Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDAOn October 26, 2023, Biosyngen’s TIL therapy BST02 for liver cancer was granted an approval for clinical trial by the US FDA. BST02, a breakthrough product in the field of cell and gene therapy, represents the world's first TIL therapy designed for the treatment of all types of liver cancer to progrREAD MORE
